Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis

We evaluated bone marrow minimal residual disease (MRD) negativity in 44 patients with light chain (AL) amyloidosis using next generation flow cytometry (sensitivity ≥1 × 10−5; median events analyzed: 8.7 million, range: 4.8 to 9.7 million). All patients underwent MRD testing in 2 years from start o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2020-05, Vol.95 (5), p.497-502
Hauptverfasser:	Sidana, Surbhi, Muchtar, Eli, Sidiqi, M. Hasib, Jevremovic, Dragan, Dispenzieri, Angela, Gonsalves, Wilson, Buadi, Francis, Lacy, Martha Q., Hayman, Suzanne R., Kourelis, Taxiarchis, Kapoor, Prashant, Go, Ronald S., Warsame, Rahma, Leung, Nelson, Rajkumar, S. Vincent, Kyle, Robert A., Gertz, Morie A., Kumar, Shaji K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Amyloidosis Bone marrow Chemotherapy Clinical trials Female Flow cytometry Flow Cytometry - methods Hematology Humans Immunoglobulin Light-chain Amyloidosis - diagnosis Light chains Male Middle Aged Minimal residual disease Neoplasm, Residual - diagnosis Neoplasm, Residual - physiopathology Patients Renal function Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!